文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

评估索非喹啉或贝达喹啉联合普托马尼和利奈唑胺治疗成人新诊断药物敏感涂片阳性肺结核安全性和有效性的2期部分盲法随机试验方案(NC-009)

Protocol for a phase 2, partially blinded, randomized trial assessing the safety and efficacy of sorfequiline or bedaquiline in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis (NC-009).
PubMed 文献 · Trials · 2026-01-06

NC-009是一项在格鲁吉亚、南非、坦桑尼亚、乌干达和菲律宾开展的2期多中心部分盲法随机试验,纳入涂片阳性药物敏感肺结核成人患者,设五个治疗组,包括三种剂量索非喹啉联合普托马尼和利奈唑胺治疗8周后根据第15周是否达到停药标准给予7或18周HR,以及BPaL组和标准治疗组(均26周)。主要目标是基于疗效和安全性数据确定索非喹啉推进至潜在3期研究的最佳剂量。

要点

  • 索非喹啉为第二代二芳基喹啉,可能提高疗效和安全性并缩短药物敏感及耐药结核治疗方案。
  • 试验设三个索非喹啉剂量组、一个BPaL组和一个标准治疗组,共五个治疗组。
  • 索非喹啉组治疗8周后根据第15周是否达到停药标准给予7或18周HR。

核心结论

  • NC-009是索非喹啉首次用于患者的剂量范围2期试验,采用融合2a、2b和2c期的创新设计,可同时进行剂量选择、疗程初步评价、安全性数据收集、与抗逆转录病毒药物相互作用评价及研究药物药代动力学评估。
  • 研究正在进行中。

研究设计与样本

  • NC-009为2期多中心部分盲法随机临床试验,在格鲁吉亚、南非、坦桑尼亚、乌干达和菲律宾开展,遵循ICH-GCP并经所有相关国家卫生主管部门和伦理委员会批准。
  • 研究设五个治疗组,包括三种剂量索非喹啉联合普托马尼和利奈唑胺治疗8周后根据第15周是否达到停药标准给予7或18周HR,以及BPaL组和标准治疗组,两者疗程均为26周。
  • 研究人群为涂片阳性药物敏感肺结核成人患者。
  • 主要目标是基于疗效和安全性数据确定索非喹啉推进至潜在3期研究的最佳剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In 2023, tuberculosis (TB) returned to being the world's leading cause of death from a single infectious agent. Current standard of care for drug-sensitive tuberculosis (DS-TB) treatment has a long duration with risk of poor compliance and outcomes and increased risk of development of resistant strains. Sorfequiline (S) is a second-generation diarylquinoline with the potential to contribute both to increased efficacy and improved safety and to a shorter TB treatment regimen for both DS-TB and drug-resistant DR-TB. METHODS AND ANALYSIS: NC-009 is a phase 2, multicentre, partially blinded, randomized clinical trial conducted in five treatment arms, including three doses of sorfequiline in combination with pretomanid and linezolid for 8 weeks followed by 7 or 18 weeks of HR depending on the participant meeting criteria to stop treatment at week 15. There is also a BPaL arm and standard of care arm, both for a 26-week treatment duration. The study population is smear-positive, DS-TB. The primary objective of the study is to determine the optimal dose of sorfequiline to move forward to a potential phase 3 study based on efficacy and safety data. The study is being conducted in Georgia, South Africa, Tanzania, Uganda, and the Philippines in accordance with ICH-GCP and after approval of all relevant country health authorities and ethics committees. DISCUSSION: NC-009 is a first in-patient, dose-ranging, phase 2 trial of sorfequiline, with an innovative design combining ph2a, ph2b, and ph2c elements that simultaneously allow for dose selection, preliminary evaluation of treatment duration, robust collection of safety data, evaluation of drug-drug interaction with antiretroviral medications, and pharmacokinetic assessment of study drugs. The study is currently ongoing. TRIAL REGISTRATION NUMBER {4}: ClinicalTrials.gov NCT06058299. Registered on 09 September 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Olugbosi M, Beumont M, Lombard L, et al. Protocol for a phase 2, partially blinded, randomized trial assessing the safety and efficacy of sorfequiline or bedaquiline in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis (NC-009). Trials. 2026. PMID: 41495827. doi:10.1186/s13063-025-09413-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。